Work

Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.4503

Authors: Brian I. Rini, Viktor Grünwald, Mayer N. Fishman, Bohuslav Melichar, Takeshi Ueda, Petr A Karlov, A H. Bair, Ying Chen, Sinil Kim, Eric Jonasch

Institutions: Cleveland Clinic, Medizinische Hochschule Hannover, Moffitt Cancer Center, University Hospital Olomouc, Chiba Cancer Center, City Clinical Oncology Center, Pfizer (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2300524408

Cites:

Cited by: 36

Related to: 10